Larimar Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| LRMR | PRQR | NKTR | LTGO | FULC | LYCA | |
|---|---|---|---|---|---|---|
| Market cap | 286.72M | 198.98M | 1.31B | 930.84M | 287.96M | 1.51B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.6 | -3.0 | -3.7 | -6.7 | -6.9 | — |
| Price/book | 2.3 | 2.2 | 1.5 | -0.1 | 0.9 | -3.2 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −20.46% | −36.20% | −30.19% | −23.07% | −50.72% | −3.60% |
| Today | +8.66% | +2.92% | +1.91% | −3.64% | +0.80% | +4.78% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All LRMR news ›Larimar Therapeutics Reports Second Quarter 2026 Financial and Business Update
BALA CYNWYD, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its second quarter…
Larimar Therapeutics Reports Positive Open Label Data and Submission of First Module of Rolling BLA for Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia
As of June 2026, 43 adolescent and adult participants in the OL study had received at least one dose of nomlabofusp and 22 participants remain in the study with a maximum treatment duration of more than 800 days. Among the study…
Larimar Therapeutics, Inc. Stock 12‑Month Price Target Raised to $14.89, Implies 451% Upside
TradingView Larimar Therapeutics, Inc. Stock 12‑Month Price Target Raised to $14.89, Implies 451% Upside - According to estimates from 9 analysts, Larimar Therapeutics, Inc. stock's average price target has
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- larimar.gcs-web.com1
- tradingview.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.